Ethambutol-induced optic neuropathy: should we mandate ophthalmic examination in TB treatment?

Kumar, S R and Hissar, S.S, S S and Ramesh, P M and Shanmugam, M and Kalaiselvan, V. and Prakash, J and Padmapriyadarsini, C (2024) Ethambutol-induced optic neuropathy: should we mandate ophthalmic examination in TB treatment? Ethambutol-induced optic neuropathy: should we mandate ophthalmic examination in TB treatment?, 28 (1). pp. 51-53.

Text 202404.pdf Download (1MB)

Abstract

India’s National Tuberculosis Elimination Programme (NTEP)1 and the WHO have recommended ethambutol (EMB) for use in the continuation phase of TB treatment due to the higher prevalence of isoniazid resistance in the patient community. This leaves only a single drug in the continuation phase that might adversely affect treatment outcomes.2 While reporting adverse drug reactions (ADRs), we found that EMB often induced optic neuropathy during anti-TB therapy (ATT) for drugsusceptible TB (DS-TB). In the study presented here, we define these ADRs and recommend adopting safety precautions when treating DS-TB patients.

Affiliation:	ICMR-National Institute for Research in Tuberculosis
Item Type:	Article
URI:	http://eprints.nirt.res.in/id/eprint/1995

Actions (login required)

View Item